Phase 1 N=70 Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 30; 31 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 Safety Trial of Live Attenuated Influenza (H7N3) Vaccine
Influenza · Avian Influenza
Primary: Number of Participants With Immediate Reactions — 0; 0; 0; 0 Participants
Phase 1 N=15 Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)
Cancer, Advanced
Primary: Lag Time (Tlag) of Ridaforolimus: Day 1 — 2.00 Hours
Phase 1 N=42 Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
Renal Impairment
Primary: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf) — 104; 141; 83.5; 244 µM*hr
Phase 1 N=9 First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects
Tuberculosis
Primary: Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A — 1; 1; 1; 3 Participants
Phase 1 N=12 Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
Hypogonadism
Primary: Maximum Concentration (Cmax) for Serum Testosterone and Testosterone Enanthate — 773.7; 1487.0; 49.25; 267.33 ng/dL
Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Phase 1 N=18 Study of Danirixin in Japanese Healthy Elderly Male Subjects
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1 — 1; 0; 0; 1 Participants
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Phase 1 N=146 A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C
Renal Transplantation
Primary: Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (INF) of Belatacept. — 17084539; 21579398 ng.h/mL
Phase 1 N=341 A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
Herpes Zoster · Herpes Zoster-related Complications
Primary: Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) — 2.35; 1.28; 1.37…
Phase 1 N=42 A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
Healthy
Primary: Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin — 80; 78 hours times nanogram per milliliter
Phase 1 N=80 Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain
Pain, Postoperative
Primary: SPID0-8h — -50.14; -24.06; -77.54; 124.47 units on scale
Phase 1 N=280 Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 88; 27 Participants
Phase 1 N=40 Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 14; 13 Participants